Quick Facts
Plain-English Summary
KPV is a synthetic tripeptide comprising three amino acids — Lysine, Proline, and Valine — representing the C-terminal fragment of alpha-Melanocyte-Stimulating Hormone (α-MSH). The parent molecule, α-MSH, is a 13-amino-acid neuropeptide produced naturally from proopiomelanocortin (POMC) cleavage in the pituitary and peripheral tissues. Research in the 1990s demonstrated that the C-terminal tripeptide KPV retained a meaningful proportion of α-MSH's anti-inflammatory activity in isolation, making it an attractive study subject for inflammatory conditions — particularly those involving the gut.
KPV's primary proposed action is inhibition of the NF-κB signalling pathway, a master regulator of inflammatory gene expression. In cell culture and rodent studies, KPV reduces pro-inflammatory cytokine production (IL-1β, IL-6, TNF-α) and attenuates intestinal inflammation scores in chemically induced colitis models. This activity appears to operate through both melanocortin receptor-dependent and receptor-independent mechanisms, giving KPV a broader mechanistic profile than simple MC1R agonism alone.
Gut health is the primary research focus. Multiple rodent studies have examined KPV in models of inflammatory bowel disease, intestinal permeability, and mucosal wound healing, finding reductions in inflammation markers and improved histological scores. Separately, in vitro data suggests KPV may accelerate wound closure in skin fibroblast models, and some animal work points to systemic anti-inflammatory effects beyond the gastrointestinal tract.
The entirety of the KPV evidence base is preclinical. No registered human clinical trial for KPV has been published or completed as of August 2026. Community claims about gut healing and IBD treatment in humans are not supported by any controlled clinical evidence.
Because KPV is a very small peptide (MW 340.42 Da), it faces rapid degradation by circulating peptidases when administered orally, raising significant questions about systemic bioavailability. Experimental nanoparticle-encapsulation strategies for oral delivery have been explored in animal models to address this limitation, but these formulations are not available in consumer markets. The subcutaneous route is standard in research contexts. As of 2026, there is no established dosing protocol, no human pharmacokinetic data, and no peer-reviewed evidence that KPV produces therapeutic effects in people.
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|---|---|
| Mouse TNBS colitis | Intracolonic KPV reduced macroscopic damage scores and colonic myeloperoxidase (MPO) activity. Colonic IL-1β and TNF-α mRNA significantly reduced vs. vehicle controls. Effect observed at doses of 0.5–5 μg per animal. Catania et al. (multiple) ↗ | Preclinical |
| Rat DSS colitis | Subcutaneous KPV attenuated disease activity index scores and histological inflammation grade. Reduction in colon shortening observed relative to untreated DSS controls. Nanoparticle-encapsulated oral KPV produced comparable results in a separate rodent study. Laroui et al. ↗ | Preclinical |
| Murine wound healing (skin) | Topical and systemic KPV accelerated wound closure rates in excisional wound models. Effect attributed to anti-inflammatory action enabling faster epithelialisation rather than direct fibroblast stimulation. Luger et al. 1997 ↗ | Preclinical |
| In vitro — macrophage activation | KPV (10–100 nM) inhibited LPS-induced IL-1β and TNF-α release in RAW264.7 macrophages. NF-κB nuclear translocation reduced by ~60% vs. LPS-alone control. Effect partially retained in MC1R-null cells, confirming receptor-independent component. Brzoska et al. 2008 ↗ | Preclinical |
| Mouse intestinal permeability | KPV reduced FITC-dextran translocation across inflamed intestinal epithelium in ex vivo Ussing chamber preparations and in vivo instillation models. Tight junction protein expression partially restored. No gut-systemic PK data reported. | Preclinical |
| Rat systemic inflammation (LPS) | Systemic KPV reduced LPS-induced fever and plasma TNF-α in rodents, consistent with parent α-MSH's known antipyretic profile. Effect magnitude smaller than full-length α-MSH at equivalent molar doses. | Preclinical |
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|---|---|---|
| Inflammatory bowel disease (IBD) | No human trial registered or published as of August 2026. IBD evidence is entirely rodent-model data. | — | No Data |
| Wound healing | No human trial registered or published. Wound healing data is limited to murine excisional models and in vitro fibroblast studies. | — | No Data |
| Systemic anti-inflammatory use | No human pharmacokinetic, safety, or efficacy data exists. No dose-ranging study in humans has been published. | — | No Data |
| All other indications | No trials registered on ClinicalTrials.gov or EU CTR as of August 2026. | — | No Data |
KPV has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
No significant acute toxicity has been observed in rodent studies at doses used in anti-inflammatory research. Given KPV's small size and its origin as an endogenous peptide fragment, severe systemic toxicity at low doses would not be expected — but the absence of toxicology studies specifically designed for KPV means this remains an assumption rather than an established finding.
MC1R agonism has potential immunomodulatory consequences in complex inflammatory conditions. Broad NF-κB suppression, if achieved systemically, could theoretically impair host defence against pathogens or interfere with tumour immunosurveillance. These risks are hypothetical in the context of KPV but are mechanistically plausible and have not been evaluated in long-duration human studies.
- Injection site redness or mild discomfort
- Transient GI discomfort with oral dosing
- Fatigue reported by some users in early days of use
- No pharmacovigilance database exists for KPV
- No systematic adverse event collection in humans
- Active or suspected malignancy
- Active infection or sepsis
- Pregnancy or breastfeeding
- Immunosuppressive therapy
- Autoimmune conditions on active treatment
- Children and adolescents
KPV is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of KPV for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of August 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume
The NF-κB inhibition story for KPV is genuinely interesting mechanistically — particularly the receptor-independent component. The Brzoska review covers this well: the C-terminal tripeptide retains a meaningful fraction of α-MSH's anti-inflammatory potency at the signalling level, which is surprising given how much you're stripping away from the parent peptide. What I can't find anywhere is credible human PK data. The tripeptide is going to face aggressive degradation by DPP-IV and other circulating peptidases. Nobody in the self-experimentation community seems to be asking whether they're actually getting any systemic exposure at the doses they're using.
This is the right question. The intracolonic delivery data from the nanoparticle encapsulation studies (Laroui et al.) is the most compelling because it sidesteps the systemic PK problem entirely — you're getting local exposure at the colonic mucosa without relying on intact peptide surviving first-pass and circulating peptidases. That's not what people are doing when they inject KPV subcutaneously, though. The translational logic there is much murkier.
I see a lot of people in IBD communities treating the TNBS and DSS colitis mouse data as near-direct evidence for human Crohn's or UC. These are chemical insult models — they produce rapid, severe intestinal inflammation that responds to almost any anti-inflammatory intervention. The histological improvement numbers look dramatic in these models, but the translation rate to human IBD has been notoriously poor across dozens of compounds over 30 years. KPV may well have genuine activity in humans, but the mouse colitis data alone is nowhere near sufficient evidence to draw that conclusion.
The part of KPV's mechanism that I find most intellectually honest is that it's not purely an MC1R story. Getting et al. showed meaningful anti-inflammatory activity persisting in MC1R-deficient (recessive yellow) mice. That suggests the tripeptide has a secondary route of action — most likely direct interference with NF-κB upstream kinases. The problem is that broad NF-κB suppression is a double-edged sword. It's the same pathway you want active for host defence and tumour immunosurveillance. Nobody in the self-experimentation community is thinking about what chronic low-grade NF-κB inhibition does to their infection response.
Fair point and worth emphasising. α-MSH itself has a therapeutic safety window in the literature because the parent neuropeptide is endogenous and subject to normal regulatory feedback. A synthetic fragment administered exogenously at doses chosen by community consensus — with no PK data — is a different risk profile. Worth being explicit about that distinction.
Honest summary of where KPV sits: the mechanistic story is coherent and the animal IBD data is real, but the gap between that and human therapeutic use is substantial. The most credible near-term application would be local colonic delivery — something like the nanoparticle approach — for IBD, where you'd be delivering KPV directly to the inflamed mucosa and bypassing the systemic degradation problem. Systemic subcutaneous dosing for "leaky gut" or vague inflammatory conditions is much further from the evidence base and much harder to justify. Until there's a Phase I safety trial with human PK data, this compound sits firmly in the research compound category.